Home Cart Sign in  
Chemical Structure| 1229705-06-9 Chemical Structure| 1229705-06-9

Structure of Idasanutlin
CAS No.: 1229705-06-9

Chemical Structure| 1229705-06-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Idasanutlin (RG7388) is a potent and selective MDM2 antagonist that inhibits p53-MDM2 binding with an IC50 of 6 nM.

Synonyms: RG7388; Ro 5503781

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Idasanutlin

CAS No. :1229705-06-9
Formula : C31H29Cl2F2N3O4
M.W : 616.48
SMILES Code : O=C(O)C1=CC(OC)=C(NC([C@H]2[C@H](C3=C(F)C(Cl)=CC=C3)[C@](C4=CC=C(Cl)C=C4F)(C#N)[C@H](CC(C)(C)C)N2)=O)C=C1
Synonyms :
RG7388; Ro 5503781
MDL No. :MFCD26142931
InChI Key :TVTXCJFHQKSQQM-LJQIRTBHSA-N
Pubchem ID :53358942

Safety of Idasanutlin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MV4-11 0.6 –2000 nM 72 h To evaluate the effects of Idasanutlin and Venetoclax alone or in combination on cell viability, showing synergistic anti-tumor activity in p53 wild-type AML cell lines. PMC4924270
MOLM-13 0.6 –2000 nM 72 h To evaluate the effects of Idasanutlin and Venetoclax alone or in combination on cell viability, showing synergistic anti-tumor activity in p53 wild-type AML cell lines. PMC4924270
OCI-AML-3 0.6 –2000 nM 72 h To evaluate the effects of Idasanutlin and Venetoclax alone or in combination on cell viability, showing synergistic anti-tumor activity in p53 wild-type AML cell lines. PMC4924270
HL-60 0.6 –2000 nM 72 h To evaluate the effects of Idasanutlin and Venetoclax alone or in combination on cell viability, showing synergistic anti-tumor activity in p53 wild-type AML cell lines. PMC4924270
DDLPS cell line IB111 2-50 nM 72 hours RG7388 significantly inhibited the proliferation of IB111 cells and induced apoptosis PMC5477309
DDLPS cell line IB115 2-50 nM 72 hours RG7388 significantly inhibited the proliferation of IB115 cells and induced apoptosis PMC5477309
MOLT-4 cells 0.5 μM 48 hours To investigate the effect of Idasanutlin on the proliferation and apoptosis of MOLT-4 cells, the results showed that Idasanutlin treatment significantly reduced cell proliferation and increased apoptosis. PMC8807395
MOLT-3 cells 30, 60, 90 nM 72 hours Idasanutlin treatment induced apoptosis of MOLT-3 control cells but not the p53 knockout lines PMC10681904
DFCI12 cells 1.5 μM 72 hours Idasanutlin treatment induced expression of the TP53 target genes BAX,BBC3 (Puma), and CDKN1A (p21) at the RNA and protein levels, and resulted in a modest increase in apoptosis PMC10681904

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NOD SCID gamma (NSG) mice Oral 30 mg/kg From conception to weaning (28 days) To test the anti-leukemic efficacy of RG in AML mouse models, results showed that the combination of RG and ABT significantly prolonged mouse survival PMC5730338
Mice Subcutaneous and orthotopic xenograft models Oral 100 mg/kg Daily administration for 2 weeks To evaluate the anti-tumor effects of Idasanutlin and Venetoclax alone or in combination in subcutaneous and orthotopic AML xenograft models, showing significantly superior efficacy of the combination treatment. PMC4924270
Mice DDLPS xenograft model Oral gavage 20 mg/kg Single injection followed by 21 days of hypoxia exposure and 14 days of normoxia reexposure RG7388 significantly inhibited tumor growth and prolonged progression-free survival PMC5477309
Mice Phf6 KO and JAK3M511I-induced T-ALL mouse model Oral gavage 1 mg/kg/day for three weeks To investigate the effect of Idasanutlin in combination with Tofacitinib on Phf6 KO and JAK3M511I-induced T-ALL mouse model, the results showed that the combination therapy significantly prolonged survival and reduced leukemia burden. PMC8807395
Mice T-ALL xenograft models Oral 3PO: 25 mg/kg/day, SU5416: 10 mg/kg/day Once daily for 5 days Combination treatment with idasanutlin and navitoclax showed marked synergic response in all four T-ALL xenografts, with a significant increase in overall survival PMC10681904

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03287245 Polycythemia Vera PHASE2 TERMINATED 2020-03-03 Mayo Clinic - Arizona, Phoenix... More >>, Arizona, 85054, United States|University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, 66205, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Cleveland Clinic Cancer Center, Independence, Ohio, 44131, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, 78229, United States|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, 3002, Australia|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, 24127, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, 21100, Italy|Az. Ospedaliero-Universitaria Careggi; CRIMM, Firenze, Toscana, 50134, Italy Less <<
NCT03362723 Solid Tumors PHASE1 COMPLETED 2019-06-11 University of Colorado, Aurora... More >>, Colorado, 80045-2517, United States|Yale Cancer Center; Medical Oncology, New Haven, Connecticut, 06520, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, 89169, United States|University of Oklahoma Health Sciences Center; Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75230, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, H3T 1E2, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.62mL

0.32mL

0.16mL

8.11mL

1.62mL

0.81mL

16.22mL

3.24mL

1.62mL

 

Historical Records

Categories